NeoGenomics (NEO) Tops Q1 EPS by 2c, reaffirms outlook

NeoGenomics (NASDAQ: NEO) reported Q1 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $156 million versus the consensus estimate of $149.89 million.

GUIDANCE:

NeoGenomics sees FY2024 revenue of $650-660 million, versus the consensus of $654.7 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Aspire Biopharma to acquire automotive supplier for $30 million
• Lennar Corp. (LEN) Misses Q2 EPS by 1c